The long‐term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch BioDay Registry

BACKGROUND: The hands are a common predilection site of atopic dermatitis (AD). Dupilumab is licensed for the treatment of AD but not for chronic hand eczema (CHE), while CHE is challenging to treat. OBJECTIVES: To evaluate the long‐term effect of dupilumab on hand eczema (HE) in patients with AD fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Voorberg, Angelique N., Romeijn, Geertruida L. E., de Bruin‐Weller, Marjolein S., Schuttelaar, Marie L. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545501/
https://www.ncbi.nlm.nih.gov/pubmed/35279856
http://dx.doi.org/10.1111/cod.14104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545501/
https://www.ncbi.nlm.nih.gov/pubmed/35279856
http://dx.doi.org/10.1111/cod.14104

Ejemplares similares